The apolipoprotein gene: a modulating role on brain volume and cognitive function in carriers of the fragile X premutation

dc.contributor.authorPoonnada Jiraanont
dc.contributor.authorJun Yi Wang
dc.contributor.authorBlythe Durbin-Johnson
dc.contributor.authorYe Hyun Hwang
dc.contributor.authorDavid Hessl
dc.contributor.authorSusan M. Rivera
dc.contributor.authorRandi J. Hagerman
dc.contributor.authorFlora Tassone
dc.date.accessioned2026-05-08T19:26:17Z
dc.date.issued2026-2-3
dc.description.abstractFragile X-associated tremor/ataxia syndrome (FXTAS), caused by the FMR1 premutation allele, is associated with brain degeneration, yet the mechanisms behind this neurodegeneration still need to be elucidated. Apoε polymorphism has been widely implicated in brain aging in cognitively healthy individuals and brain deterioration in Alzheimer's disease. This study aimed to examine the interaction of Apoε genotypes, FXTAS clinical symptoms, FMR1 molecular measures, and age, towards brain pathophysiology and cognitive functions. This longitudinal study includes MRI data collected from 205 male premutation carriers with and without FXTAS clinical symptoms and compared to 86 healthy male controls aged 40-85 years. The investigation includes FXTAS-related brain volumes, IQ, self-control behaviors, FMR1 molecular measures, and Apoε genotypes. In carriers with FXTAS, the presence of the Apoε2 allele showed a possible association with more favorable neuroimaging markers, such as reduced white matter hyperintensities, and lower incidence of the middle cerebellar peduncle sign, patterns that were not observed in carriers without FXTAS. Specifically, the presence of Apoε2 allele exhibited a potential protective effect on brain degeneration, and cognitive functions among FXTAS patients; on the contrary, the Apoε4 allele was associated with a worsening of brain volume and brain degeneration in carriers with no FXTAS symptoms. The identification of Apoε genotypes in FMR1 premutation carriers before any clinical symptoms of FXTAS are observed may improve symptomatic management leading to better outcomes for these individuals.
dc.identifier.doi10.1016/j.nbd.2026.107292
dc.identifier.urihttps://dspace.kmitl.ac.th/handle/123456789/20515
dc.publisherNeurobiology of Disease
dc.subjectGenetics and Neurodevelopmental Disorders
dc.subjectGenetic Neurodegenerative Diseases
dc.subjectUbiquitin and proteasome pathways
dc.titleThe apolipoprotein gene: a modulating role on brain volume and cognitive function in carriers of the fragile X premutation
dc.typeArticle

Files

Collections